Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer

Treatment options for patients with metastatic colorectal cancer (mCRC) are limited. This particularly affects the largest group of patients with RAS mutations, who are considered ineligible for therapy with antiEGFR antibodies. In this liquid biopsy-based study, we performed the first in-depth anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein-Scory, Susanne, Wahner, Ingo, Maslova, Marina, Al-Sewaidi, Yosef, Pohl, Michael, Mika, Thomas, Ladigan, Swetlana, Schroers, Roland, Baraniskin, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378792/
https://www.ncbi.nlm.nih.gov/pubmed/32766143
http://dx.doi.org/10.3389/fonc.2020.01115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378792/
https://www.ncbi.nlm.nih.gov/pubmed/32766143
http://dx.doi.org/10.3389/fonc.2020.01115

Ejemplares similares